IP Library Granted Patent US 7,351,584
Granted Patent B2
US 7,351,584 · App. 10/505,785 · Granted Apr 1, 2008

Hepatocyte bioreactor system for long term culture of functional hepatocyte spheroids

Assignee: In Vitro Technologies, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,351,584
App. No.
10/505,785
Granted
Apr 1, 2008
Kind
B2
Abstract

A rotating wall vessel is used as a culture vessel and bioreactor for the cultivation of hepatocytes in the form of spheroids to generate a culture with many properties of the intact liver. These properties include enzyme activity comparable to fresh cells and long-term maintenance of viability and cellular function for periods on the order of months. The cultures may be used to produce hepatocyte products, evaluate metabolism of an agent, propagate Hepatitis C virus and test agents as inhibitors of this virus. Thus, the culture system disclosed herein makes long term functional cultivation of human hepatocytes feasible.

Claims (24)

1. A method for cultivation of mammalian hepatocytes in a viable functional state, which comprises the steps of:

(a) culturing a single cell suspension of mammalian hepatocytes in a culture medium for a period of between about 12 and about 168 hours in a culture vessel having a flat surface under conditions that permit aggregation of hepatocytes into spheroids which comprise viable hepatocytes;

(b) transferring said spheroids into a rotating wall vessel (RVW) culture chamber where said spheroids remain substantially in suspension during subsequent culture with rotation; and

(c) incubating said suspended spheroids under conditions of vessel rotation such that said spheroids remain substantially in suspension;

wherein suspended spheroids remain viable and capable of:

(i) producing and secreting normal hepatocyte products; and

(ii) metabolizing drugs or toxins via enzymes of the cytochrome P450 system, which drugs or toxins are ones that are normally metabolized by hepatocytes in vivo for more than 30 days.

2. The method of claim 1 wherein the RWV is a High Aspect Ratio Vessel (HARV).

3. The method of claim 1 wherein the culturing of step (a) is for a time of between about 24 and about 72 hours.

4. The method of claim 1 wherein the culture vessel of step (a) is a plastic petri dish.

5. The method of claim 1 wherein the culture medium is selected from the group consisting of Waymouth MB 752, Williams' Medium E, Eagle's MEM; Dulbecco's MEM/Ham's F12, RPMI 1640, and Leibovitz L-15 medium.

6. The method of claim 1 wherein the culture medium is supplemented with serum.

7. The method of claim 1 wherein the culture medium is supplemented with:

(a) one or more growth factors, and/or

(b) one or more peptide hormones, and/or

(c) one or more glucocorticoids

which growth factors, hormones and glucocorticoids promote the viability and metabolic activity of the hepatocytes.

8. The method of claim 7 wherein said growth factors comprise epidermal growth factor, said hormones comprise insulin or glucagon; and said glucocorticoids comprise dexamethasone or hydrocortisone.

9. The method of claim 1 wherein said hepatocytes are primate hepatocytes.

10. The method of claim 9 wherein said primate hepatocytes are human hepatocytes.

11. A method for cultivation of mammalian hepatocytes in a viable functional state, which comprises inoculating a High Aspect Ratio Vessel (HARV) with pre-aggregated hepatocytes or nascent hepatocyte spheroids, in a culture medium and incubating said hepatocytes and under conditions wherein hepatocytes are viable and metabolically active for a period of at least about 4 days:

wherein said hepatocytes remain viable and capable of:

(i) producing and secreting normal hepatocyte products; and

(ii) metabolizing drugs or toxins via enzymes of the cytochrome P450 system, which drugs or toxins are ones that are normally metabolized by hepatocytes in vivo for more than 30 days.

Assignments (16)
RELEASE OF SECURITY INTEREST AT REEL/FRAME NO. 037408/0099 Recorded Oct 4, 2021
From: GOLUB CAPITAL LLC
To: IN VITRO, INC.
Reel/Frame 057698/0182 →
SECURITY INTEREST Recorded Oct 4, 2021
From: IN VITRO, INC.; QUALYST TRANSPORTER SOLUTIONS LLC; ASCENDANCE BIOTECHNOLOGY, INC.
To: ARES CAPITAL CORPORATION
Reel/Frame 057686/0762 →
RELEASE OF SECURITY INTEREST Recorded Jan 6, 2016
From: GOLUB CAPITAL LLC, AS ADMINISTRATIVE AGENT
To: IN VITRO, INC.
Reel/Frame 037422/0342 →
SECURITY INTEREST Recorded Jan 5, 2016
From: IN VITRO, INC.
To: GOLUB CAPITAL LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 037408/0099 →
RELEASE OF SECURITY INTEREST Recorded Jun 23, 2014
From: BROWN BROTHERS HARRIMAN & CO., AS ADMINISTRATIVE AGENT
To: CELSIS IN VITRO, INC.
Reel/Frame 033217/0051 →
CHANGE OF NAME Recorded Jun 10, 2014
From: CELSIS IN VITRO, INC.
To: IN VITRO, INC.
Reel/Frame 033114/0433 →
ASSIGNMENT OF SECURITY INTEREST IN PATENTS Recorded Jun 9, 2014
From: ABACUS FINANCE GROUP, LLC, AS ADMINISTRATIVE AGENT
To: GOLUB CAPITAL LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 033106/0921 →
SECURITY AGREEMENT Recorded Jul 2, 2013
From: CELSIS IN VITRO, INC.
To: ABACUS FINANCE GROUP, LLC, AS AGENT
Reel/Frame 030745/0323 →
SECURITY AGREEMENT Recorded Mar 21, 2013
From: CELSIS IN VITRO, INC.
To: BROWN BROTHERS HARRIMAN & CO., AS ADMINISTRATIVE AGENT
Reel/Frame 030055/0686 →
RELEASE OF SECURITY INTEREST Recorded Mar 11, 2013
From: KBC BANK NV
To: CELSIS IN VITRO, INC.
Reel/Frame 029959/0326 →
SECURITY AGREEMENT Recorded Jan 27, 2010
From: CELSIS IN VITRO, INC.
To: KBC BANK NV
Reel/Frame 023854/0652 →
CHANGE OF NAME Recorded Jan 24, 2010
From: IN VITRO TECHNOLOGIES, INC.
To: CELSIS IN VITRO, INC.
Reel/Frame 023832/0814 →
RELEASE OF SECURITY INTEREST Recorded Jan 13, 2010
From: BARCLAYS BANK PLC
To: CELSIS IN VITRO INC.
Reel/Frame 023768/0838 →
CHANGE OF NAME Recorded Jan 4, 2010
From: IN VITRO TECHNOLOGIES, INC.
To: CELSIS IN VITRO, INC.
Reel/Frame 023720/0785 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 18, 2007
From: SILBER, PAUL M.; COWGER, NANCY L.; MILLER, ANA P.; BROWN, LANIKA A.; LI, ALBERT P.
To: IN VITRO TECHNOLOGIES, INC.
Reel/Frame 020260/0445 →
SECURITY AGREEMENT Recorded Apr 6, 2007
From: IN VITRO TECHNOLOGIES, INC.
To: BARCLAYS BANK PLC
Reel/Frame 019122/0755 →
Continuity (1)
Related Publication 20050084965A1 · Apr 21, 2005